FDA Approves Roche Breast Cancer Drug Giredestrant; Childhood Weight-Loss Drug Trial Results Released

Written by

in

The U.S. FDA approved Roche’s breast cancer drug giredestrant, paving the way for the drug’s commercialization for additional breast cancer indications. A trial published by ObesityWeek showed that nearly 40% of children aged 6 to 11 with severe obesity no longer had obesity after taking semaglutide for 68 weeks, compared with 0% in the placebo group.

Source:STAT · Read Original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *